{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-11215"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-11215","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Developing a Point-of-Care Detection kit for Parkinson’s Disease Using Gold Nanoparticle-Based Lateral Flow Assay","abstract":"Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease and the fastest-growing neurodegenerative disorder in the world. The major issue with PD is that it takes several years of biological changes until the patient starts to experience physiological symptoms that could affect their daily lives. The major hallmark of PD is the appearance of Lewy body inclusions in the neuron’s cytoplasm, which is rich in a protein called α-Synuclein (α-Syn). Several studies have shown that the levels of α-Syn in blood increase because the excess α-Syn is released from neurons into the bloodstream through extracellular vesicles. This makes it an excellent biomarker for diagnosing and monitoring patient progress or treatment response. α-Syn is the most extensively studied biomarker for diagnosing PD. Developing a point-of-care technique to detect changes in the aggregated α-Syn in the blood is urgently needed and essential for early PD diagnosis. The current method commonly used to detect α-Syn is ELISA, or PCR, which could take a few hours and needs lab skills. Therefore, we developed a lateral flow immunoassay using an anti-mouse monoclonal antibody (2A4) and a polyclonal antibody (G93-115) for rapid detection in blood samples within 30 minutes using just the naked eye. The results that were observed using LFA was similar to those that were detected with ELISA","abstract_html":"Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease and the fastest-growing neurodegenerative disorder in the world. The major issue with PD is that it takes several years of biological changes until the patient starts to experience physiological symptoms that could affect their daily lives. The major hallmark of PD is the appearance of Lewy body inclusions in the neuron’s cytoplasm, which is rich in a protein called α-Synuclein (α-Syn). Several studies have shown that the levels of α-Syn in blood increase because the excess α-Syn is released from neurons into the bloodstream through extracellular vesicles. This makes it an excellent biomarker for diagnosing and monitoring patient progress or treatment response. α-Syn is the most extensively studied biomarker for diagnosing PD. Developing a point-of-care technique to detect changes in the aggregated α-Syn in the blood is urgently needed and essential for early PD diagnosis. The current method commonly used to detect α-Syn is ELISA, or PCR, which could take a few hours and needs lab skills. Therefore, we developed a lateral flow immunoassay using an anti-mouse monoclonal antibody (2A4) and a polyclonal antibody (G93-115) for rapid detection in blood samples within 30 minutes using just the naked eye. The results that were observed using LFA was similar to those that were detected with ELISA","abstract_has_math":false,"creators":["Aljassabi, Ali"],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Pharmacy","degree_department":null,"school":null,"contributors":["Chuanhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023-10-22T07:00:00Z","date_published":"2023-10-22T07:00:00Z","updated_at":"2026-11-19T08:49:07Z","subjects":["Parkinson’s disease","α-synuclein","gold nanoparticles","Lateral Flow Immunoassay","Medicinal Chemistry and Pharmaceutics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/10018","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/10018","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-11215","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Chuanhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Aljassabi, Ali"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023-10-22T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Parkinson’s disease","α-synuclein","gold nanoparticles","Lateral Flow Immunoassay","Medicinal Chemistry and Pharmaceutics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/10018"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease and the fastest-growing neurodegenerative disorder in the world. The major issue with PD is that it takes several years of biological changes until the patient starts to experience physiological symptoms that could affect their daily lives. The major hallmark of PD is the appearance of Lewy body inclusions in the neuron’s cytoplasm, which is rich in a protein called α-Synuclein (α-Syn). Several studies have shown that the levels of α-Syn in blood increase because the excess α-Syn is released from neurons into the bloodstream through extracellular vesicles. This makes it an excellent biomarker for diagnosing and monitoring patient progress or treatment response. α-Syn is the most extensively studied biomarker for diagnosing PD. Developing a point-of-care technique to detect changes in the aggregated α-Syn in the blood is urgently needed and essential for early PD diagnosis. The current method commonly used to detect α-Syn is ELISA, or PCR, which could take a few hours and needs lab skills. Therefore, we developed a lateral flow immunoassay using an anti-mouse monoclonal antibody (2A4) and a polyclonal antibody (G93-115) for rapid detection in blood samples within 30 minutes using just the naked eye. The results that were observed using LFA was similar to those that were detected with ELISA"]},{"key":"dc:title","label":"Title","values":["Developing a Point-of-Care Detection kit for Parkinson’s Disease Using Gold Nanoparticle-Based Lateral Flow Assay"]}]}],"canonical_facts":{"dc:contributor":["Chuanhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."],"dc:creator":["Aljassabi, Ali"],"dc:date":["2023-10-22T07:00:00Z"],"dc:description":["Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease and the fastest-growing neurodegenerative disorder in the world. The major issue with PD is that it takes several years of biological changes until the patient starts to experience physiological symptoms that could affect their daily lives. The major hallmark of PD is the appearance of Lewy body inclusions in the neuron’s cytoplasm, which is rich in a protein called α-Synuclein (α-Syn). Several studies have shown that the levels of α-Syn in blood increase because the excess α-Syn is released from neurons into the bloodstream through extracellular vesicles. This makes it an excellent biomarker for diagnosing and monitoring patient progress or treatment response. α-Syn is the most extensively studied biomarker for diagnosing PD. Developing a point-of-care technique to detect changes in the aggregated α-Syn in the blood is urgently needed and essential for early PD diagnosis. The current method commonly used to detect α-Syn is ELISA, or PCR, which could take a few hours and needs lab skills. Therefore, we developed a lateral flow immunoassay using an anti-mouse monoclonal antibody (2A4) and a polyclonal antibody (G93-115) for rapid detection in blood samples within 30 minutes using just the naked eye. The results that were observed using LFA was similar to those that were detected with ELISA"],"dc:identifier":["https://digitalcommons.usf.edu/etd/10018"],"dc:subject":["Parkinson’s disease","α-synuclein","gold nanoparticles","Lateral Flow Immunoassay","Medicinal Chemistry and Pharmaceutics"],"dc:title":["Developing a Point-of-Care Detection kit for Parkinson’s Disease Using Gold Nanoparticle-Based Lateral Flow Assay"],"thesis:degree_discipline":["Pharmacy"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:49:07Z"}